新華醫療(600587.SH):控股股東戰略重組交割完成
格隆匯11月30日丨新華醫療(600587.SH)公佈,公司接到間接控股股東山東能源通知,獲悉2020年11月30日,山東能源與兗礦集團有限公司簽署了《交割確認書》,雙方於2020年8月14日簽署的《山東能源集團有限公司與兗礦集團有限公司之合併協議》所約定的本次合併交割前提已全部滿足,本次合併可以進行交割;本次合併的交割日為2020年11月30日(含當日);自2020年11月30日,本次合併予以交割;雙方按照《合併協議》約定辦理具體交割事項。
本次合併完成後,公司的直接控股股東和實際控制人未發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.